Answers are grounded in this paper and cite their sources.
Targeting CSF-1 with neutralizing antibodies halts EAE progression by selectively depleting inflammatory myeloid cells, offering a potential targeted therapy for multiple sclerosis.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Shiu et al. (1983) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: